Edition:
United Kingdom

Incyte Corp (INCY.OQ)

INCY.OQ on NASDAQ Stock Exchange Global Select Market

69.05USD
19 Apr 2018
Change (% chg)

-- (--)
Prev Close
$69.05
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
689,400
52-wk High
$140.07
52-wk Low
$61.30

Chart for

About

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI... (more)

Overall

Beta: 0.81
Market Cap(Mil.): $24,161.52
Shares Outstanding(Mil.): 210.65
Dividend: --
Yield (%): --

Financials

  INCY.OQ Industry Sector
P/E (TTM): -- 84.02 32.74
EPS (TTM): -0.78 -- --
ROI: -11.99 1.58 14.38
ROE: -23.24 2.41 16.07

FDA staff raises safety concerns over Lilly/Incyte arthritis drug

An experimental rheumatoid arthritis drug developed by Eli Lilly and Co and Incyte Corp poses serious risks of deadly blood clots at higher doses, U.S. Food and Drug Administration staff said on Thursday, the latest setback to a treatment regulators declined to approve last year.

19 Apr 2018

UPDATE 2-Incyte tumbles after combo therapy with Merck fails study

April 6 Incyte Corp's shares sank more than 20 percent on Friday after its experimental cancer drug failed to bolster the effectiveness of Merck & Co's blockbuster Keytruda to treat skin cancer patients.

06 Apr 2018

Incyte, Merck melanoma combo therapy fails study, shares slide

Incyte Corp said on Friday an independent committee concluded that its drug for a type of skin cancer in combination with Merck & Co's Keytruda failed to meet the main goal in a late-stage study.

06 Apr 2018

Incyte's combo therapy for skin cancer fails in late-stage study

April 6 Incyte Corp said on Friday an independent committee concluded that its drug in combination with Merck & Co's Keytruda for a type of skin cancer failed to meet the main goal in a late-stage study.

06 Apr 2018

BRIEF-Incyte, Merck Provide Update On Phase 3 Study

* INCYTE AND MERCK PROVIDE UPDATE ON PHASE 3 STUDY OF EPACADOSTAT IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) IN PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA

06 Apr 2018

BRIEF-Incyte CEO ‍​Hervé Hoppenot's 2017 Total Compensation Was $16.1 Mln Vs $11.8 Mln

* INCYTE CORP - CEO ‍​HERVÉ HOPPENOT'S 2017 TOTAL COMPENSATION WAS $16.1 MILLION VERSUS $11.8 MILLION - SEC FILING Source text: (http://bit.ly/2GsaYcC) Further company coverage:

14 Mar 2018

BRIEF-Incyte Corp Q4 Loss Per Share $0.71

* INCYTE REPORTS 2017 FOURTH-QUARTER AND YEAR-END FINANCIAL RESULTS, PROVIDES 2018 FINANCIAL GUIDANCE AND UPDATES ON KEY CLINICAL PROGRAMS

15 Feb 2018

BRIEF-Incyte Updates Conference Call Time To Report Fourth Quarter And Year-End Financial Results

* INCYTE UPDATES CONFERENCE CALL TIME TO REPORT FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS Source text for Eikon: Further company coverage:

31 Jan 2018

BRIEF-Syros Pharmaceuticals Enters Amendment To Stock Purchase Agreement With Incyte

* SYROS PHARMACEUTICALS -‍ ON JAN 31, ENTERED AMENDMENT NO. 1 TO STOCK PURCHASE AGREEMENT WITH INCYTE TO FACILITATE PRIVATE PLACEMENT - SEC FILING​

31 Jan 2018

BRIEF-Incyte Corp Recommends Shareholders Reject Mini-Tender Offer By TRC Capital

* INCYTE CORPORATION RECOMMENDS SHAREHOLDERS REJECT MINI-TENDER OFFER BY TRC CAPITAL CORPORATION

23 Jan 2018

Competitors

  Price Chg
Pfizer Inc. (PFE.N) $36.53 --
Abbott Laboratories (ABT.N) $59.88 --
Amgen, Inc. (AMGN.OQ) $172.93 --
Biogen Inc (BIIB.OQ) $266.02 --
Roche Holding Ltd. (ROG.S) CHF216.60 +0.10
Roche Holding Ltd. (RO.S) CHF219.80 -0.40
Sanofi SA (SASY.PA) €65.51 -0.09

Earnings vs. Estimates